Elina Alaterre
YOU?
Author Swipe
View article: The de novo DNA methyltransferase 3B is a novel epigenetic regulator of MYC in multiple myeloma, representing a promising therapeutic target to counter relapse
The de novo DNA methyltransferase 3B is a novel epigenetic regulator of MYC in multiple myeloma, representing a promising therapeutic target to counter relapse Open
Background The plasma cell malignancy multiple myeloma (MM) remains incurable due to the inevitable development of drug resistance (DR). Epigenetic modifiers are frequently mutated or deregulated in MM patients, contributing to MM progress…
View article: Integrative single-cell chromatin and transcriptome analysis of human plasma cell differentiation
Integrative single-cell chromatin and transcriptome analysis of human plasma cell differentiation Open
Plasma cells (PCs) are highly specialized cells representing the end stage of B-cell differentiation. We have shown that PC differentiation can be reproduced in vitro using elaborate culture systems. The molecular changes occurring during …
View article: EZH2 targeting induces CD38 upregulation and response to anti-CD38 immunotherapies in multiple myeloma
EZH2 targeting induces CD38 upregulation and response to anti-CD38 immunotherapies in multiple myeloma Open
International audience
View article: The BLM helicase is a new therapeutic target in multiple myeloma involved in replication stress survival and drug resistance
The BLM helicase is a new therapeutic target in multiple myeloma involved in replication stress survival and drug resistance Open
Multiple myeloma (MM) is a hematologic cancer characterized by accumulation of malignant plasma cells in the bone marrow. To date, no definitive cure exists for MM and resistance to current treatments is one of the major challenges of this…
View article: miRNA profile at diagnosis predicts treatment outcome in patients with B-chronic lymphocytic leukemia: A FILO study
miRNA profile at diagnosis predicts treatment outcome in patients with B-chronic lymphocytic leukemia: A FILO study Open
During many years, chemo-immunotherapy fludarabine-cyclophosphamide-rituximab (FCR) was the gold standard for first line treatment of medically fit patients with symptomatic B-chronic lymphocytic leukemia (CLL). Over the last decade, targe…
View article: Var|Decrypt: a novel and user-friendly tool to explore and prioritize variants in whole-exome sequencing data
Var|Decrypt: a novel and user-friendly tool to explore and prioritize variants in whole-exome sequencing data Open
Motivation High throughput sequencing (HTS) offers unprecedented opportunities for the discovery of causative gene variants in multiple human disorders including cancers, and has revolutionized clinical diagnostics. However, despite more t…
View article: PIM2 kinase has a pivotal role in plasmablast generation and plasma cell survival, opening up novel treatment options in myeloma
PIM2 kinase has a pivotal role in plasmablast generation and plasma cell survival, opening up novel treatment options in myeloma Open
The differentiation of B cells into plasmablasts (PBs) and then plasma cells (PCs) is associated with extensive cell reprogramming and new cell functions. By using specific inhibition strategies (including a novel morpholino RNA antisense …
View article: Comprehensive characterization of the epigenetic landscape in Multiple Myeloma
Comprehensive characterization of the epigenetic landscape in Multiple Myeloma Open
Background: Human multiple myeloma (MM) cell lines (HMCLs) have been widely used to understand the molecular processes that drive MM biology. Epigenetic modifications are involved in MM development, progression, and drug resistance. A comp…
View article: RNA-Sequencing-Based Transcriptomic Score with Prognostic and Theranostic Values in Multiple Myeloma
RNA-Sequencing-Based Transcriptomic Score with Prognostic and Theranostic Values in Multiple Myeloma Open
Multiple myeloma (MM) is the second most frequent hematological cancer and is characterized by the clonal proliferation of malignant plasma cells. Genome-wide expression profiling (GEP) analysis with DNA microarrays has emerged as a powerf…
View article: The Anti-Cancer Drug Dabrafenib Is a Potent Activator of the Human Pregnane X Receptor
The Anti-Cancer Drug Dabrafenib Is a Potent Activator of the Human Pregnane X Receptor Open
The human pregnane X receptor (hPXR) is activated by a large set of endogenous and exogenous compounds and plays a critical role in the control of detoxifying enzymes and transporters regulating liver and gastrointestinal drug metabolism a…
View article: High Content Screening Using New U2OS Reporter Cell Models Identifies Harmol Hydrochloride as a Selective and Competitive Antagonist of the Androgen Receptor
High Content Screening Using New U2OS Reporter Cell Models Identifies Harmol Hydrochloride as a Selective and Competitive Antagonist of the Androgen Receptor Open
Prostate cancer is the most commonly diagnosed malignancy in men. Its growth mainly relies on the activity of the androgen receptor (AR), justifying the use of androgen deprivation therapy as a gold standard treatment for the metastatic di…
View article: <i>CD24</i>, <i>CD27</i>, <i>CD36</i> and <i>CD302</i> gene expression for outcome prediction in patients with multiple myeloma
<i>CD24</i>, <i>CD27</i>, <i>CD36</i> and <i>CD302</i> gene expression for outcome prediction in patients with multiple myeloma Open
Multiple myeloma (MM) is a B cell neoplasia characterized by clonal plasma cell (PC) proliferation. Minimal residual disease monitoring by multi-parameter flow cytometry is a powerful tool for predicting treatment efficacy and MM outcome. …
View article: Automated and simplified identification of normal and abnormal plasma cells in Multiple Myeloma by flow cytometry
Automated and simplified identification of normal and abnormal plasma cells in Multiple Myeloma by flow cytometry Open
Background Multiple myeloma (MM) is an incurable disease characterized by clonal plasma cell (PC) proliferation within the bone marrow (BM). Next‐generation flow cytometry has become the reference tool to follow minimal residual disease (M…